OS Therapies Incorporated
$1.77
-$0.06 (-3.28%)
$1.76Day Range$1.83
Key Statistics
Market Cap
$85.65M
Shares Outstanding
46.8M
Primary Exchange
XASE
Currency
USD
Type
CS
IPO Date
Aug 1, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$1.81
Day High
$1.83
Day Low
$1.76
Volume
908.6K
VWAP
$1.78
Prev Close
$1.83
Transactions
--
Acc. Volume
--
About OS Therapies Incorporated
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
PHARMACEUTICAL PREPARATIONSSIC 28345 employees15825 SHADY GROVE ROAD, ROCKVILLE, MD, 20850410-297-7793IPO Aug 1, 2024US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001795091
- Composite FIGI
- BBG00Y71N7G7
- Share Class FIGI
- BBG00Y71N7H6
- Ticker Root
- OSTX
- SIC Code
- 2834
About OS Therapies Incorporated (OSTX) Stock
OS Therapies Incorporated (OSTX) closed the 2026-09-18 session at $1.77, down 3.28% versus the previous close (-0.06). The stock opened at $1.81 and traded between $1.76 and $1.83 during that session. Session trading volume was 909K shares. The volume-weighted average price (VWAP) is $1.78.
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
OS Therapies Incorporated has a market capitalization of $85.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. OSTX is listed on the XASE exchange. The company employs approximately 5 people. OS Therapies Incorporated is headquartered in ROCKVILLE, MD. The recorded listing date is 2024-08-01.
On this page you can find market OSTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.